Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma or tumor of the brain. While ventricular brain lymphoma is even rarer, its clinical characteristics and treatment strategies remain less explored. Now, researchers have evaluated the clinical features of PCNSL lesions involving the ventricles. They found that this rare tumor type shares key features with other brain lymphomas, suggesting a unified treatment approach.

A new review in Chinese Medical Journal highlights exosomes’ role in obstructive sleep apnea (OSA)-related diseases. OSA’s intermittent hypoxia alters exosome cargo, driving cellular dysfunction linked to cardiovascular issues, diabetes, neurodegeneration, and cancer, while exosomes also show therapeutic potential.

Gynecological cancers remain a major threat to women's health, with traditional therapies often having limited effect and severe side effects. A new class of "“Magic bullets", known as Antibody-Drug Conjugates (ADCs), is now changing the game. With the first ADC for cervical cancer already approved and more in development for ovarian and uterine cancers, new hope is emerging for patients with recurrent disease. A literature review published in SCIENCE CHINA Life Sciences provides a comprehensive overview of ADCs, synthesizing existing evidence from ongoing clinical trials and preclinical studies in gynecological cancers. It examines the adverse reactions associated with ADCs and explores strategies to mitigate these adverse effects, thereby enhancing the efficacy of ADCs in treating gynecological malignancies.

A recent comprehensive analysis highlights the transformative potential of Metal-Organic Frameworks (MOFs)—highly porous, tunable materials—in pharmaceutical research. The review concludes that MOFs can dramatically improve drug loading, enable targeted release to disease sites, and enhance the stability of delicate therapeutics, paving the way for more effective and precise treatments for conditions ranging from cancer to pulmonary diseases.